@article {MASTREN201875,
	title = {Chromatographic separation of the theranostic radionuclide 111Ag from a proton irradiated thorium matrix},
	journal = {Analytica Chimica Acta},
	volume = {998},
	year = {2018},
	pages = {75 - 82},
	abstract = {Column chromatographic methods have been developed to separate no-carrier-added 111Ag from proton irradiated thorium targets and associated fission products as an ancillary process to an existing 225Ac separation design. Herein we report the separation of 111Ag both prior and subsequent to 225Ac recovery using CL resin, a solvent impregnated resin (SIR) that carries an organic solution of alkyl phosphine sulfides (R3P~=~S) and alkyl phosphine oxides (R3P~=~O). The recovery yield of 111Ag was 93~{\textpm}~9\% with a radiochemical purity of 99.9\% (prior) and 87~{\textpm}~9\% with a radiochemical purity of 99.9\% (subsequent to) 225Ac recovery. Both processes were successfully performed with insignificant impacts on 225Ac yields or quality. Measured equilibrium distribution coefficients for silver and ruthenium (a residual contaminant) on CL resin in hydrochloric and nitric acid media are reported, to the best of our knowledge, for the first time. Additionally, measured cross sections for the production of 111Ag and 110mAg for the 232Th(p,f)110m,111Ag reactions are reported within.},
	keywords = {AG, CL resin, Nuclear reaction cross sections, Proton irradiation, Theranostic, Thorium target},
	issn = {0003-2670},
	doi = {https://doi.org/10.1016/j.aca.2017.10.020},
	url = {http://www.sciencedirect.com/science/article/pii/S0003267017311790},
	author = {Tara Mastren and Valery Radchenko and Jonathan W. Engle and John W. Weidner and Allison Owens and Lance E. Wyant and Roy Copping and Mark Brugh and F. Meiring Nortier and Eva R. Birnbaum and Kevin D. John and Michael E. Fassbender}
}
@article {MASTREN201724,
	title = {Bulk production and evaluation of high specific activity 186gRe for cancer therapy using enriched 186WO3 targets in a proton beam},
	journal = {Nuclear Medicine and Biology},
	volume = {49},
	year = {2017},
	pages = {24 - 29},
	abstract = {Introduction Rhenium-186g (t1/2 = 3.72 d) is a β- emitting isotope suitable for theranostic applications. Current production methods rely on reactor production by way of the reaction 185Re(n,γ)186gRe, which results in low specific activities limiting its use for cancer therapy. Production via charged particle activation of enriched 186W results in a 186gRe product with a higher specific activity, allowing it to be used more broadly for targeted radiotherapy applications. This targets the unmet clinical need for more efficient radiotherapeutics. Methods A target consisting of highly enriched, pressed 186WO3 was irradiated with protons at the Los Alamos National Laboratory Isotope Production Facility (LANL-IPF) to evaluate 186gRe product yield and quality. LANL-IPF was operated in a dedicated nominal 40 MeV mode. Alkaline dissolution followed by anion exchange chromatography was used to isolate 186gRe from the target material. Phantom and radiolabeling studies were conducted with the produced 186gRe activity. Results A 186gRe batch yield of 1.38 {\textpm} 0.09 MBq/μAh or 384.9 {\textpm} 27.3 MBq/C was obtained after 16.5 h in a 205 μA average/230μA maximum current proton beam. The chemical recovery yield was 93\% and radiolabeling was achieved with efficiencies ranging from 60{\textendash}80\%. True specific activity of 186gRe at EOB was determined via ICP-AES and amounted to 0.788 {\textpm} 0.089 GBq/μg (0.146 {\textpm} 0.017 GBq/nmol), which is approximately seven times higher than the product obtained from neutron capture in a reactor. Phantom studies show similar imaging quality to the gold standard 99mTc. Conclusions We report a preliminary study of the large-scale production and novel anion exchange based chemical recovery of high specific activity 186gRe from enriched 186WO3 targets in a high-intensity proton beam with exceptional chemical recovery and radiochemical purity.},
	keywords = {high specific activity, radiolabeling, RE, SPECT phantom images, Theranostic, WO target},
	issn = {0969-8051},
	doi = {https://doi.org/10.1016/j.nucmedbio.2017.02.006},
	url = {http://www.sciencedirect.com/science/article/pii/S0969805116304176},
	author = {Tara Mastren and Valery Radchenko and Hong T. Bach and Ethan R. Balkin and Eva R. Birnbaum and Mark Brugh and Jonathan W. Engle and Matthew D. Gott and James Guthrie and Heather M. Hennkens and Kevin D. John and Alan R. Ketring and Marina Kuchuk and Joel R. Maassen and Cleo M. Naranjo and F. Meiring Nortier and Tim E. Phelps and Silvia S. Jurisson and D. Scott Wilbur and Michael E. Fassbender}
}
